Secondary debulking for ovarian carcinoma relapse: The R-R dilemma – is the prognosis different for residual or recurrent disease?

Autor: Spiliotis JD; Department of Surgical Oncology and HIPEC, Athens Medical Centre, Athens, Greece; Department of Surgical Oncology and HIPEC, European Interbalkan Medical Centre, Thessaloniki, Greece, Iavazzo C; Clinic of Gynecological Oncology, Metaxa Cancer Hospital, Piraeus, Greece, Kopanakis ND; Clinic of Surgical Oncology, Metaxa Cancer Hospital, Piraeus, Greece, Christopoulou A; Clinic of Medical Oncology, Saint Andrews Hospital, Patra, Greece

Publikováno v: Journal of the Turkish German Gynecological Association [J Turk Ger Gynecol Assoc] 2019 Nov 28; Vol. 20 (4), pp. 213-217. Date of Electronic Publication: 2019 Jul 31.

Adipose microenvironment promotes hypersialylation of ovarian cancer cells.

Autor: Fox, Alexandra, Leonard, Garry D., Adzibolosu, Nicholas, Wong, Terrence, Tedja, Roslyn, Sharma, Sapna, Gogoi, Radhika, Morris, Robert, Mor, Gil, Fehl, Charlie, Alvero, Ayesha B.

Publikováno v: Frontiers in Oncology; 2024, p1-14, 14p

Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.

Autor: Gómez-Ruiz, Álvaro Jesús, González-Gil, Alida, Gil, José, Navarro-Barrios, Álvaro, Alconchel, Felipe, Gil, Elena, Martínez, Jerónimo, Nieto, Aníbal, Barceló, Francisco, Cascales-Campos, Pedro Antonio

Publikováno v: Clinical & Experimental Metastasis; Oct2019, Vol. 36 Issue 5, p433-439, 7p